its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward than its prevention. It comprises of oxygenation ...

Your healthcare team can best advise you on treatment for COPD exacerbations. If you live with chronic obstructive pulmonary disease (COPD), you may experience shortness of breath, wheezing ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

The FDA approval of Airsupra permits use for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Arterial-Blood Studies during Treatment of Severe Refractory Bronchial Asthma in Case 2 on May 17, after Theophylline and Epinephrine (1), at 8:00 A.M., when the Asthma Was Refractory to ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Allergy specialist care lowers asthma emergency risks in children on Medicaid, highlighting its value in management.

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...